Pseudothrombocytopenia Associated With Multiple Myeloma

Reed, Bryan W.; Go, Ronald S.
July 2006
Mayo Clinic Proceedings;Jul2006, Vol. 81 Issue 7, p869
Academic Journal
The article presents the medical case of a 90-year old woman with pseudothrombocytopenia associated with multiple myeloma. Her peripheral blood smear showed massive platelet agglutination. The disease was detected just before the diagnosis of multiple myeloma where platelet autoantibodies disappeared after the multiple myeloma responded to chemotherapy and coincided with resolution of the pseudothrombocytopenia.


Related Articles

  • Extramedullary progression of multiple myeloma despite a good response in the bone marrow in a patient following autologous stem cell transplantation. Kose, Mustafa; Sonnez, Mehmet; Cobanoglu, Umit; Yilmaz, Mustafa; Karti, S. Sami; Ovali, Ercument; Ozoran, Yavuz // Turkish Journal of Cancer;Apr2003, Vol. 33 Issue 2, p102 

    Extramedullary plasmacytomas may be seen in the course of multiple myeloma. However, extramedullary progression despite good response in the bone marrow to therapy is extremely rare. Recently, two cases of multiple with extramedullary progression despite continued response to thalidomide in the...

  • Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Kobayashi, T.; Kuroda, J.; Ashihara, E.; Oomizu, S.; Terui, Y.; Taniyama, A.; Adachi, S.; Takagi, T.; Yamamoto, M.; Sasaki, N.; Horiike, S.; Hatake, K.; Yamauchi, A.; Hirashima, M.; Taniwaki, M. // Leukemia (08876924);Apr2010, Vol. 24 Issue 4, p843 

    Galectins constitute a family of lectins that specifically exhibit the affinity for β-galactosides and modulate various biological events. Galectin-9 is a tandem-repeat type galectin with two carbohydrate recognition domains and has recently been shown to have an anti-proliferative effect on...

  • Cure of multiple myeloma – more hype, less reality. Hari, P.; Pasquini, M. C.; Vesole, D. H. // Bone Marrow Transplantation;Jan2006, Vol. 37 Issue 1, p1 

    Randomized studies have firmly established the role of autologous transplant as initial therapy in multiple myeloma (MM). Indeed, MM has emerged as the commonest indication for autologous SCT in North America. The conceptual basis for high-dose therapy is the goal of complete remission (CR)...

  • A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Hong Suk Song; Young Rok Do; Heung Moon Chang; Min Hee Ryu; Kyung Hee Lee; Yeul Hong Kim; Dae Sik Hong; Jae Yong Cho; Kyoung Eun Lee; Si Young Kim // Cancer Chemotherapy & Pharmacology;Oct2008, Vol. 62 Issue 5, p763 

    This open-label, multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus gemcitabine combination chemotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. We enrolled 63 patients who received capecitabine...

  • A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. Jian Hou; Xin Du; Jie Jin; Zhen Cai; Fangping Chen; Dao-bin Zhou; Li Yu; Xiaoyan Ke; Xiao Li; Depei Wu; Fanyi Meng; Huisheng Ai; Jingshan Zhang; Wortman-Vayn, Honeylet; Nianhang Chen; Jay Mei; Jianmin Wang // Journal of Hematology & Oncology;2013, Vol. 6 Issue 1, p1 

    Background: There is an unmet need for treatment options in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Lenalidomide plus low-dose dexamethasone is effective and generally well tolerated in Caucasian RRMM patients, but no previous study has evaluated this regimen in...

  • The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. R. García-Sanz Jr.; González-Porras; Hernández, J. M.; Polo-zarzuela, M.; Sureda, A.; Barrenetxea, C.; Palomera, L.; López, R.; Grande-García, C.; Alegre, A.; Vargas-Pabón, M.; Gutiérrez, O. N.; Rodríguez, J. A.; Miguel, J. F.San // Leukemia (08876924);Apr2004, Vol. 18 Issue 4, p856 

    We evaluate the efficacy of the oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) in 71 refractory/relapsed multiple myeloma patients, including a prognostic analysis to predict both response and survival. Patients received thalidomide at escalating doses (200-800...

  • Treatment of MM-associated spinal fracture with percutaneous vertebroplasty (PVP) and chemotherapy. Yang, Zuozhang; Tan, Jing; Xu, Yongqing; Sun, Hongpu; Xie, Lin; Zhao, Ruilian; Wang, Jiaping; Jiang, Hua // European Spine Journal;May2012, Vol. 21 Issue 5, p912 

    Purpose: To investigate the effect of treatment of multiple myeloma (MM)-associated spinal fracture with percutaneous vertebroplasty (PVP) and chemotherapy. Methods: Patients with MM-associated spinal fracture were randomly divided into combined (PVP and chemotherapy) treatment group ( n = 38)...

  • Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies. Gopalakrishnan, Sathish; Tan, Daryl // Blood & Lymphatic Cancer: Targets & Therapy;2013, Vol. 3, p19 

    Although the clinical outcomes of patients with multiple myeloma has improved tremendously with the advent of bortezomib and immunomodulatory drugs like thalidomide and lenalidomide, the disease remains incurable and patients will eventually be resistant to these drugs. Novel non-cross-resistant...

  • New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway. van de Donk, Niels W. C. J.; Bloem, Andries C.; Spek, Ellen v. d.; Lokhorst, Henk M. // Current Pharmaceutical Design;Jan2006, Vol. 12 Issue 3, p327 

    Insight into the mechanisms of primary or acquired drug resistance of (hematological) malignancies is critical for the development of new treatment strategies. This review will focus on Bcl-2 and the mevalonate pathway as targets for reversal of drug resistance in multiple myeloma. The Bcl-2...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics